Search | Clinical Trials Finder

Conditions: HIV Infections
Interventions: Hepatitis B Vaccine (Recombinant), gp160 Vaccine (MicroGeneSys); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1991
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Nashville, Tennessee

Conditions: HIV Infections
Interventions: Automated diary system; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 24 Years · Female only
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Tampa, Florida • Pittsburgh, Pennsylvania

Conditions: Healthy
Interventions: VCR-HIVDNA006-00-VP; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: APL 400-047, Bupivacaine hydrochloride; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2001
U.S. locations: 4
States / cities: Birmingham, Alabama • Rochester, New York • Nashville, Tennessee + 1 more

Conditions: HIV Infections
Interventions: rAd5 Gag-Pol Env A/B/C, rAd5 Gag-Pol; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York

Conditions: HIV Infections
Interventions: P3C541b Lipopeptide; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 3
States / cities: Baltimore, Maryland • Nashville, Tennessee • Seattle, Washington

Conditions: HIV Infections
Interventions: Behavioral counseling, HIV-1 Antibody Test Kit; Other · Device
Lead sponsor: bioLytical Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 14
States / cities: Los Angeles, California • Palm Springs, California • San Diego, California + 8 more

Conditions: Sexually Transmitted Diseases, HIV Infections
Interventions: CenteringPregnancy, CenteringPregnancyPlus, Usual care; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 14 Years to 25 Years · Female only
Enrollment: 1,047 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2008
U.S. locations: 2
States / cities: New Haven, Connecticut • Atlanta, Georgia

Conditions: HIV Infections
Interventions: Naphthalene 2-sulfonate polymer, Carbopol polymer; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1997
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HIV Infections
Interventions: Affect Management, General Health Promotion; Behavioral
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 13 Years to 18 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: HIV Infections, HIV Seronegativity
Interventions: ALVAC-HIV MN120TMG (vCP205); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2001
U.S. locations: 6
States / cities: Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more

Conditions: HIV Infections
Interventions: HIVAC-1e, gp160 Vaccine (MicroGeneSys); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1993
U.S. locations: 1
States / cities: Rochester, New York

Conditions: HIV Infections
Interventions: HIV-1 Peptide Vaccine, Microparticulate Monovalent, HIV-1 Peptide Immunogen, Multivalent; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 3
States / cities: Birmingham, Alabama • Rochester, New York • Seattle, Washington

Conditions: Opiate Dependence, HIV Infections
Interventions: Enhanced Sexual Risk Management, Standard Sexual Risk Management; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: HIV, HIV Infections
Interventions: Video, in-person HIV pre-test counseling; Behavioral
Lead sponsor: North Bronx Healthcare Network; Other
Eligibility: 15 Years to 21 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: HIV Infections, Sexually Transmitted Diseases
Interventions: HORIZONS HIV Intervention, enhanced standard-of-care; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 15 Years to 21 Years · Female only
Enrollment: 715 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2005
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: HIV Infections
Interventions: ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65), rgp120/HIV-1 SF-2; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1997
U.S. locations: 6
States / cities: Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more

Conditions: HIV Infections
Interventions: gp160 Vaccine (Immuno-AG), rgp120/HIV-1IIIB, rgp120/HIV-1MN, rgp120/HIV-1 SF-2, HIVAC-1e; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1994
U.S. locations: 2
States / cities: Rochester, New York • Seattle, Washington

Conditions: Hepatitis B, Hepatitis C, HIV Infection
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 3,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: APL 400-047, ALVAC-HIV MN120TMG (vCP205), Sargramostim; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1999
U.S. locations: 4
States / cities: Birmingham, Alabama • Baltimore, Maryland • Rochester, New York + 1 more

Conditions: HIV Infections
Interventions: DNA Vaccine, DNA Vaccine placebo, rAd35, rAd35 placebo, rAd5, rAd5 placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 10
States / cities: Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more

Conditions: HIV Infections
Interventions: MN rgp120/HIV-1 and GNE8 rgp120/HIV-1, ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2000
U.S. locations: 6
States / cities: Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more

Conditions: HIV Infections
Interventions: SOLVE-IT; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 24 Years · Male only
Enrollment: 2,020 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV Infections
Interventions: Community Mobilization; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 12 Years to 24 Years
Enrollment: 4,472 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 4 more

Search by objective public record fields.

A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

Microbicides Acceptability Among Sexually Active Young Women

HIV-1 Vaccine Test in Uninfected Adult Volunteers

A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers

Antigenic Competition in HIV Preventive Vaccines

A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human Subjects

Testing of INSTI™ HIV-1 Antibody Test Kit in Volunteer Subjects at Risk for HIV Infection

Group Prenatal Care for Reducing the Risk of STDs in Pregnant Young Women

Effects of BufferGel and PRO 2000/5 Gel in Men

An Affect Management Intervention for Juvenile Offenders

A Study of the Effectiveness of an HIV Vaccine (ALVAC vCP205) to Boost Immune Functions in HIV-Negative Volunteers Who Have Already Received an HIV Vaccine

A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency Virus

A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.

Reducing Sex-Related HIV Risk Behaviors in Patients Receiving Treatment for Opioid Dependence

Video-based Counseling & Rapid HIV Testing for Teens

HORIZONS HIV Intervention

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) in HIV-1 Uninfected Adult Volunteers

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals

Frequency of Parenteral and Non-Parenteral Exposures to Blood Among Healthcare Workers at the Clinical Center, NIH and at Seven Academic Hospitals in Japan

A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers

Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector

A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers

The SOLVE-IT National Randomized Trial

C2P (With Venues): Connect to Protect® Partnerships For Youth Prevention Interventions